Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
You may also be interested in...
Keytruda's Path From 32-Patient Study To Approval
KEYNOTE-001 started as a small, Phase I trial in melanoma but morphed into a 1,200-patient registrational study for two indications and a companion diagnostic.
Merck’s Oncology Strategy: Digging In With Expansion Of Keytruda
With Keytruda, Merck has shown it has the wherewithal to compete in immuno-oncology against more experienced rivals. Now, as management outlined at ASCO, the company is digging its heels into the field, studying Keytruda in 30 tumor types and evaluating other early stage assets.
Merck Expands Keytruda Trial Collaboration With Amgen, Unveils Others
Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO.